{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:47:47Z","timestamp":1769269667523,"version":"3.49.0"},"reference-count":22,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed\/refractory multiple myeloma (RRMM). Materials and Methods: This study evaluates the real-world effectiveness and safety of IRd in Croatian RRMM patients. A retrospective analysis was conducted on 164 RRMM patients treated with ixazomib at nine Croatian haematology centres from November 2016 to February 2023. Data on patient demographics, treatment regimens, and outcomes were collected and analysed using Kaplan\u2013Meier survival curves and Cox proportional hazards models in R. The median age at ixazomib initiation was 66 years (range 40\u201391). Results: The overall response rate (ORR) was 65.8%, with 42% of patients achieving a very good partial response (VGPR) or better. The median progression-free survival (PFS) was 15.4 months, while median overall survival (OS) was 28.2 months. Hematologic toxicities included anaemia (53%), neutropenia (50%), and thrombocytopenia (45%). Infective complications, primarily COVID-19 and pneumonia, were reported in 38% of patients. The safety profile was consistent with previous studies, indicating manageable adverse events. Ixazomib-based therapy is effective and well tolerated in a real-world Croatian RRMM population. Conclusions: The findings align with clinical trial results, demonstrating the applicability of ixazomib in routine clinical practice. Further studies are needed to optimise treatment sequencing and improve patient outcomes.<\/jats:p>","DOI":"10.3390\/medicina60111905","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T10:37:35Z","timestamp":1732099055000},"page":"1905","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)"],"prefix":"10.3390","volume":"60","author":[{"given":"Josip","family":"Batini\u0107","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Dreta","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Rin\u010di\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sisters of Charity Hospital, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2960-5444","authenticated-orcid":false,"given":"Antonia","family":"Mrde\u017ea","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sisters of Charity Hospital, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-8811","authenticated-orcid":false,"given":"Karla Mi\u0161ura","family":"Jakobac","sequence":"additional","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delfa Radi\u0107","family":"Kri\u0161to","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Division of Hematology, Clinical Hospital Merkur, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-2225","authenticated-orcid":false,"given":"Milan","family":"Vuj\u010di\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Split, 21000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Pir\u0161i\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017deljko","family":"Jonji\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlatka","family":"Peri\u0161a","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Centre Osijek, 31000 Osijek, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasminka","family":"Sin\u010di\u0107 Petri\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Centre Osijek, 31000 Osijek, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017eena","family":"Coha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital \u201cDr. Josip Ben\u010devi\u0107\u201d, 35000 Slavonski Brod, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital \u201cDr. Josip Ben\u010devi\u0107\u201d, 35000 Slavonski Brod, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Valkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Specialty Hospital Medico, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Stani\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-305X","authenticated-orcid":false,"given":"Ivan","family":"Kre\u010dak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital \u0160ibenik, 22000 \u0160ibenik, Croatia"},{"name":"School of Medicine, University of Rijeka, 51000 Rijeka, Croatia"},{"name":"University of Applied Sciences, 22000 Sibenik, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9310-4426","authenticated-orcid":false,"given":"Ante","family":"Stojanovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6367-1264","authenticated-orcid":false,"given":"Domagoj","family":"Sajfert","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Ba\u0161i\u0107-Kinda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and Paradigms in Multiple Myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17474086.2017.1285694","article-title":"Triplet combinations in relapsed\/refractory myeloma: Update on recent phase 3 trials","volume":"10","author":"Boudreault","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Leleu, X., Masszi, T., Bahlis, N.J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O., Rosi\u00f1ol, L., and Langer, C. (Am. J. Hematol., 2018). Patient-Reported Health-Related Quality of Life From the Phase III TOURMALINE-MM1 Study of Ixazomib-Lenalidomide-Dexamethasone Versus Placebo-Lenalidomide-Dexamethasone in Relapsed\/Refractory Multiple Myeloma, Am. J. Hematol., Epub ahead of print.","DOI":"10.1002\/ajh.25134"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CIA.S89465","article-title":"Multiple myeloma in the very elderly patient: Challenges and solutions","volume":"11","author":"King","year":"2016","journal-title":"Clin. Interv. Aging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"EHA SWG on \u2018Aging and Hematology\u2019. Elderly patients with multiple myeloma: Towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.critrevonc.2019.02.011","article-title":"Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction","volume":"137","author":"Fraz","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2019-125749","article-title":"Real-world (rw) multiple myeloma (mm) patients (pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: Analysis of over 3,000 pts from the insight mm global, prospective, observational study","volume":"134","author":"Hungria","year":"2019","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","article-title":"Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed\/Refractory Multiple Myeloma","volume":"20","author":"Chari","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jgo.2017.09.007","article-title":"The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed\/refractory multiple myeloma in the era of novel therapies","volume":"9","author":"Hari","year":"2018","journal-title":"J. Geriatr. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00277-021-04534-8","article-title":"Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed\/refractory multiple myeloma (RRMM) in the US","volume":"100","author":"Davies","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/17474086.2020.1729734","article-title":"Real-world outcomes and factors impacting treatment choice in relapsed and\/or refractory multiple myeloma (RRMM): A comparison of VRd, KRd, and IRd","volume":"13","author":"Chari","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"World Medical Association (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310, 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e7071","DOI":"10.1002\/cam4.7071","article-title":"A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma: The northern Italy experience","volume":"13","author":"Furlan","year":"2024","journal-title":"Cancer Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00277-023-05278-3","article-title":"Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: The REMIX study","volume":"102","author":"Macro","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2217\/fon-2020-1225","article-title":"Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed\/refractory multiple myeloma","volume":"17","author":"Straub","year":"2021","journal-title":"Future Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/S2152-2650(23)01876-1","article-title":"P-258 Carfilzomib in relapsed\/refractory multiple myeloma patients\u2014Real world evidence: Experiences of the Croatian cooperative group for hematologic diseases (KROHEM)","volume":"23","author":"Dreta","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S2152-2650(23)01852-9","article-title":"P-234 Daratumumab in relapsed\/refractory multiple myeloma patients\u2014Real world evidence\u2014Experiences of the Croatian cooperative group for hematologic diseases (KROHEM)","volume":"23","author":"Dreta","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1905\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:36:10Z","timestamp":1760114170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["medicina60111905"],"URL":"https:\/\/doi.org\/10.3390\/medicina60111905","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]}}}